FTRE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

663.84M

-4.76%

0.166

-8.03%

659.22M

+1.22%

0.133

+566.8%

678.99M

-4.41%

0.188

-1.08%

Estimates Revision

The market is revising Upward the revenue expectations for Fortrea Holdings Inc. (FTRE) for FY2025, with the revenue forecasts being adjusted by 0.27% over the past three months. During the same period, the stock price has changed by 61.77%.

Revenue Estimates for FY2025

Revise Upward

+0.27%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.81%

In Past 3 Month

Stock Price

Go Up

+61.77%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast FTRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTRE is 11.19 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

7 Hold

2 Sell

Hold

Current: 0.000

Low

7.00

Averages

11.19

High

14.00

Current: 0.000

Low

7.00

Averages

11.19

High

14.00

Truist

Jailendra Singh

Hold

Buy

upgrade

$22

2026-01-08

New

Reason

Truist

Jailendra Singh

Price Target

$22

2026-01-08

New

upgrade

Hold

Buy

Reason

Truist analyst Jailendra Singh upgraded Fortrea to Buy from Hold with a $22 price target. The firm cites the company's improving execution under new leadership, early signs of commercial momentum, and a "relatively clearer path" to margin recovery for the upgrade. Fortrea investor sentiment is turning more constructive as the new CEO focuses on commercial excellence, operational efficiency, and financial discipline, the analyst tells investors in a research note.

Evercore ISI

In Line -> Outperform

upgrade

$14 -> $25

2026-01-06

New

Reason

Evercore ISI

Price Target

$14 -> $25

2026-01-06

New

upgrade

In Line -> Outperform

Reason

Evercore ISI upgraded Fortrea to Outperform from In Line with a price target of $25, up from $14. The firm cites the "accelerating" biopharma cycle and the company's improved performance for the upgrade. Fortrea is seeing higher revenue and margins versus consensus estimates, and is also benefiting from deleveraging, the analyst tells investors in a research note.

Mizuho

Ann Hynes

Neutral

maintain

$11 -> $13

2025-12-18

Reason

Mizuho

Ann Hynes

Price Target

$11 -> $13

2025-12-18

maintain

Neutral

Reason

Mizuho analyst Ann Hynes raised the firm's price target on Fortrea to $13 from $11 and keeps a Neutral rating on the shares as part of its 2026 outlook for managed care and health facilities. The firm believes 2026 will be a "pivotal year" for managed care. The sector is at the end of a three-year negative underwriting cycle and margins should improve in commercial, Medicaid and Medicare over the next few years, the analyst tells investors in a research note. As a result, Mizuho is positive on managed care heading into 2026.

BofA

Buy

maintain

$7 -> $8

2025-12-15

Reason

BofA

Price Target

$7 -> $8

2025-12-15

maintain

Buy

Reason

BofA raised the firm's price target on Fortrea to $8 from $7 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.

Barclays

Luke Sergott

Underweight -> Equal Weight

upgrade

$10 -> $15

2025-12-15

Reason

Barclays

Luke Sergott

Price Target

$10 -> $15

2025-12-15

upgrade

Underweight -> Equal Weight

Reason

Barclays analyst Luke Sergott upgraded Fortrea to Equal Weight from Underweight with a price target of $15, up from $10. The firm adjusted ratings in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Citi

Neutral -> Buy

upgrade

$12 -> $21

2025-12-11

Reason

Citi

Price Target

$12 -> $21

2025-12-11

upgrade

Neutral -> Buy

Reason

Citi upgraded Fortrea to Buy from Neutral with a price target of $21, up from $12. The firm adjusted ratings in the life science tools and diagnostics group as part of its 2026 outlook. It believes Fortrea is well positioned for margin expansion and upside to consensus estimates.

Valuation Metrics

The current forward P/E ratio for Fortrea Holdings Inc (FTRE.O) is 24.84, compared to its 5-year average forward P/E of 26.65. For a more detailed relative valuation and DCF analysis to assess Fortrea Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

26.65

Current PE

24.84

Overvalued PE

42.46

Undervalued PE

10.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

12.78

Current EV/EBITDA

13.02

Overvalued EV/EBITDA

16.46

Undervalued EV/EBITDA

9.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.67

Current PS

0.58

Overvalued PS

0.98

Undervalued PS

0.36

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 105.42% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 182.65% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 105.42% over the last month.

Sold

Bought

FTRE News & Events

Events Timeline

No data

News

1.0

01-09Globenewswire

Fortrea Updates J.P. Morgan Conference Presentation Time to January 13

5.0

01-06NASDAQ.COM

VHT ETF Sees Notable Insider Buying in Fortrea and Biohaven Holdings

1.0

01-06Globenewswire

Fortrea CEO Anshul Thakral to Present at J.P. Morgan Healthcare Conference

People Also Watch

Frequently Asked Questions

What is Fortrea Holdings Inc (FTRE) stock price today?

The current price of FTRE is 17.39 USD — it has decreased -0.29 % in the last trading day.

What is Fortrea Holdings Inc (FTRE)'s business?

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

What is the price predicton of FTRE Stock?

What is Fortrea Holdings Inc (FTRE)'s revenue for the last quarter?

Fortrea Holdings Inc revenue for the last quarter amounts to 701.30M USD, increased 3.91 % YoY.

What is Fortrea Holdings Inc (FTRE)'s earnings per share (EPS) for the last quarter?

Fortrea Holdings Inc. EPS for the last quarter amounts to -0.17 USD, decreased -45.16 % YoY.

What changes have occurred in the market's expectations for Fortrea Holdings Inc (FTRE)'s fundamentals?

How many employees does Fortrea Holdings Inc (FTRE). have?

Fortrea Holdings Inc (FTRE) has 15500 emplpoyees as of January 10 2026.

What is Fortrea Holdings Inc (FTRE) market cap?

Today FTRE has the market capitalization of 1.61B USD.